What is the optimal treatment strategy for a patient infected with a pan‑drug‑resistant multidrug‑resistant organism (MDRO) that is resistant to all antibiotic classes?

Treatment of Pan-Drug-Resistant Multidrug-Resistant Organisms

For pan-drug-resistant (PDR) Gram-negative bacteria—defined as non-susceptibility to all agents in all antimicrobial categories—combination therapy with colistin plus a beta-lactam antibiotic (typically a carbapenem) represents the most evidence-supported approach, despite in vitro resistance, with clinical cure achieved in 67% of cases in the only published case series. 1

Defining the Problem

• PDR is defined as non-susceptibility to all licensed and routinely available antibiotics in all antimicrobial categories, including carbapenems, beta-lactams, fluoroquinolones, aminoglycosides, and polymyxins 2, 3
• The most common PDR organisms are Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, accounting for the majority of reported cases worldwide 4, 5
• All-cause mortality ranges from 20-71% in PDR infections, but is substantially reduced when treatment regimens with in vitro activity are used 5

Immediate Management Steps

Mandatory Consultation and Diagnostics

• Obtain immediate infectious disease consultation for all PDR infections, as this is strongly recommended for all MDRO infections and is critical for mortality reduction 6
• Obtain cultures from all relevant sites (blood, wound, respiratory, urine) before starting antibiotics to confirm the organism and resistance pattern 6
• Perform antimicrobial susceptibility testing with MIC determination and genotypic characterization (e.g., carbapenemase detection) to identify any residual susceptibility 6

Treatment Algorithm by Organism

PDR Pseudomonas aeruginosa

First-line approach:

• Combination therapy with colistin (2.5-5 mg/kg loading dose, then 2.5 mg/kg IV every 12 hours) PLUS a carbapenem (meropenem 2g IV every 8 hours as 3-hour infusion) despite documented resistance, as synergy may occur in vivo 1, 5
• If any residual susceptibility exists to newer agents, use ceftolozane-tazobactam or ceftazidime-avibactam as these have the highest efficacy against difficult-to-treat resistant Pseudomonas 4

Alternative combinations when colistin + carbapenem fails:

• Colistin + imipenem + amikacin (15-20 mg/kg IV daily) as triple therapy has shown success in case reports 4, 5
• Fosfomycin IV (if available) in combination with colistin or carbapenem, as fosfomycin demonstrates synergistic activity against carbapenem-resistant Pseudomonas 7

PDR Acinetobacter baumannii

First-line approach:

• Colistin (same dosing as above) PLUS a carbapenem (meropenem or imipenem) PLUS tigecycline (100 mg loading dose, then 50 mg IV every 12 hours) as triple combination therapy 6, 4
• Tigecycline in combination with colistimethate, imipenem, amikacin, or ampicillin-sulbactam are the most effective treatments for PDR Acinetobacter 4

Alternative approach:

• High-dose ampicillin-sulbactam (9g sulbactam component daily) PLUS colistin, as sulbactam has intrinsic activity against Acinetobacter 4

PDR Klebsiella pneumoniae and Other Enterobacterales

First-line approach:

• Ceftazidime-avibactam 2.5g IV every 8 hours infused over 3 hours if any residual susceptibility exists 6
• If truly pan-resistant, use colistin PLUS a carbapenem PLUS tigecycline as triple therapy 4, 5

Alternative agents:

• Meropenem-vaborbactam 4g IV every 8 hours or imipenem-cilastatin-relebactam 1.25g IV every 6 hours if susceptibility testing suggests potential activity 6
• Fosfomycin IV formulations (if available) in combination with other agents, as fosfomycin is recommended for CRE infections resistant to newer antibiotics 7

Critical Dosing Principles

Maximizing Pharmacodynamic Exposure

• Use extended or continuous infusions of beta-lactams (3-4 hour infusions) in critically ill patients to maximize time above MIC, even when MIC is elevated 8
• Never use monotherapy for PDR infections; synergistic combinations are essential and represent the only available option in most cases 5
• Employ high-dose, once-daily aminoglycoside dosing (amikacin 15-20 mg/kg, tobramycin 5-7 mg/kg) when used as part of combination therapy 8

Therapeutic Drug Monitoring

• Perform therapeutic drug monitoring for aminoglycosides (target peak 25-35 µg/mL, trough <2 µg/mL) to optimize efficacy while minimizing nephrotoxicity 8
• Monitor colistin levels when possible, especially in patients with renal impairment or those receiving prolonged courses 7

Treatment Duration

• Treat bloodstream infections for 7-14 days depending on source control and clinical response 7
• Treat complicated urinary tract infections for 5-7 days if source control is achieved 7
• Treat pneumonia for ≥7 days, with longer courses for immunocompromised patients 7

Monitoring and Toxicity Management

Nephrotoxicity Surveillance

• Monitor serum creatinine and BUN every 2-3 days when using colistin or aminoglycosides, as colistin causes acute kidney injury in 30-60% of critically ill patients 8
• Avoid combining colistin with aminoglycosides unless absolutely necessary, as this markedly increases nephrotoxicity risk 8

Additional Monitoring

• Obtain baseline and weekly audiometry for patients on prolonged aminoglycoside therapy to detect ototoxicity early 8
• Monitor for QTc prolongation if using fluoroquinolones, especially with baseline QTc >500 ms 8

Infection Control Measures

• Place patient in single-room isolation with contact precautions (gown and glove) immediately upon identification of PDR organism 6
• Flag the patient's electronic medical record to ensure precautions are maintained across care transitions 6
• Implement enhanced environmental disinfection protocols in affected areas 6
• Reinforce hand hygiene with alcohol-based products as the single most important measure to prevent transmission 6

Common Pitfalls to Avoid

• Never assume in vitro resistance predicts in vivo failure; colistin + carbapenem combinations have achieved clinical cure despite pan-resistance on testing 1
• Never add a single new drug to a failing regimen; always use at least two previously unused agents when revising therapy 2
• Never use intermittent therapy for drug-resistant organisms; daily dosing is mandatory except for injectable agents after initial daily therapy 2
• Never delay source control procedures (drainage, debridement, device removal); antibiotics alone are insufficient for PDR infections with undrained collections 6
• Never extend oral fluoroquinolone monotherapy beyond 14 days for any infection, as this promotes resistance without proven benefit 8

When Standard Approaches Fail

• Consider investigational agents or compassionate use protocols through infectious disease consultation 6
• Re-evaluate for non-infectious etiologies (pulmonary embolism, heart failure) that may mimic persistent infection 8
• Obtain repeat cultures to assess microbiologic response and rule out superinfection with a different organism 8
• Reassess source control adequacy; inadequate drainage or retained foreign material is the most common cause of treatment failure 6